News Travere undercuts key rival in rare kidney disease IgAN Filspari will launch for IgA Nepropathy at a discount to Calliditas' Tarpeyo, cleared in 2021.
News Calliditas hits $90m jackpot as biotech IPO craze continues Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech I
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.